Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
141
×
national blog main
life sciences
national top stories
biotech
san francisco blog main
new york blog main
san francisco top stories
new york top stories
san diego blog main
clinical trials
national
san diego top stories
seattle blog main
raleigh-durham blog main
fda
raleigh-durham top stories
wisconsin blog main
detroit blog main
indiana blog main
seattle top stories
wisconsin top stories
boston
detroit top stories
texas blog main
texas top stories
boulder/denver blog main
indiana top stories
boulder/denver top stories
deals
startups
cancer
eli lilly
pfizer
investing
gene therapy
novartis
sanofi
amgen
What
drug
bio
new
roundup
medicines
medicine
fda
cancer
medical
life
ipo
therapeutics
gene
drugs
boston
disease
million
companies
health
week
digital
patients
tech
therapy
biotech
science
sciences
startup
approval
company
crispr
genetic
healthcare
research
approved
big
future
team
today
ago
Language
unset
unknown
Current search:
" boston top stories "
×
@xconomy.com
4 months ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
4 months ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 months ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
5 months ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
5 months ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 months ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
5 months ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
5 months ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
5 months ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
5 months ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
6 months ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
6 months ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
7 months ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
7 months ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
8 months ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
8 months ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
9 months ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
9 months ago
Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
9 months ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
9 months ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
9 months ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
9 months ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
10 months ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
10 months ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
10 months ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
10 months ago
Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health
@xconomy.com
10 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
1 year ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
1 year ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
1 year ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
1 year ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
1 year ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
1 year ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
1 year ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
1 year ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
1 year ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
1 year ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com
1 year ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
1 year ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
1 year ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
1 year ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
1 year ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
1 year ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
1 year ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
1 year ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
1 year ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
First
Prev
Page 1
(current)
Next
Last